$351 Million is the total value of venBio Partners LLC's 9 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CMPI | Exit | CHECKMATE PHARMACEUTICALS IN | $0 | – | -3,673,374 | -100.0% | -2.60% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALX ONCOLOGY HLDGS INC | 16 | Q2 2024 | 73.8% |
| HARMONY BIOSCIENCES HLDGS IN | 16 | Q2 2024 | 21.1% |
| VERONA PHARMA PLC | 15 | Q2 2022 | 22.2% |
| AKERO THERAPEUTICS INC | 14 | Q3 2022 | 65.3% |
| PHARVARIS N V | 14 | Q2 2024 | 35.2% |
| ELEVATION ONCOLOGY INC | 13 | Q2 2024 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 11 | Q2 2021 | 62.0% |
| IMPEL PHARMACEUTICALS INC | 11 | Q4 2023 | 7.3% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 42.7% |
| PRECISION BIOSCIENCES INC | 7 | Q3 2020 | 62.0% |
View venBio Partners LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View venBio Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.